Summary of "Anxiolytic & Hypnotic Drugs"

Big-picture concepts

Anxiety is an emotional state of fear or apprehension with sympathetic signs (tachycardia, hypertension, tremor, diaphoresis, tachypnea). Pathophysiology centers on limbic system disinhibition from low GABA and low serotonin, leading to sympathetic hyperactivity and physical anxiety symptoms.
Insomnia is difficulty initiating or maintaining sleep. Key regulatory structures: pineal gland (melatonin), suprachiasmatic nucleus (SCN), ventrolateral preoptic nucleus (VLPO) in the hypothalamus, reticular formation, and posterior hypothalamus. Insomnia commonly results from disrupted communication among these centers — e.g., low melatonin, low GABA, or excess orexin/histamine → VLPO inhibited and arousal centers promoted.

Receptor and neurochemical details

Serotonin (5-HT) neurons stimulate GABAergic neurons; decreased 5-HT → less GABA release → decreased inhibition of limbic neurons.
GABA-A receptor: pentameric receptor with important alpha subunits:
- Alpha-2: primarily mediates anxiolytic effects (limbic system).
- Alpha-1: primarily mediates hypnotic/sedative effects (reticular formation).
Mechanisms of major classes:
- Benzodiazepines: positive allosteric modulators of GABA-A that increase the frequency of Cl– channel opening.
- Barbiturates: increase the duration of Cl– channel opening (more toxic; no ceiling effect).
- Z-drugs (zolpidem, zaleplon, zopiclone): bind GABA-A at alpha-1 → predominantly hypnotic effects.
- SSRIs/SNRIs: inhibit serotonin reuptake → increase synaptic 5-HT → indirectly enhance GABAergic inhibition of limbic neurons.
- Buspirone: partial 5-HT receptor agonist — anxiolytic with low abuse potential.
- Melatonin receptor agonists (ramelteon, tasimelteon): act on MT1/MT2 → inhibit SCN → activate VLPO → promote sleep.
- Orexin antagonists (e.g., suvorexant): block orexin-driven arousal.
- Antihistamines and certain antidepressants (doxepin, mirtazapine, trazodone): H1 blockade → reduced histamine-driven wakefulness → sedation.

Drug categories and key examples

Anxiolytics (aim: increase 5-HT and/or GABA activity)
- Increase serotonin
  - SSRIs: escitalopram, citalopram, paroxetine (long-term; therapeutic onset ~4–6 weeks)
  - SNRIs: venlafaxine, duloxetine
  - 5-HT receptor agonist: buspirone (chronic anxiety, low abuse potential)
- Increase GABA-A activity
  - Benzodiazepines (preferred over barbiturates for anxiolysis): alprazolam, lorazepam, clonazepam, diazepam, oxazepam, temazepam (choice guided by half-life)
  - Barbiturates (generally avoided for anxiolysis): phenobarbital, thiopental
Hypnotics (aim: promote/maintain sleep)
- Melatonin receptor agonists: ramelteon, tasimelteon — good for sleep induction; minimal dependence
- GABA-A modulators targeting alpha-1
  - Benzodiazepines for insomnia: temazepam, flurazepam (effective but risk dependence/rebound)
  - Z-drugs (alpha-1 selective): zolpidem, zaleplon, zopiclone — suitable for short-term insomnia; zaleplon has very short half-life (less morning sedation)
- Orexin receptor antagonists: suvorexant — reduces orexin-driven arousal
- Antihistamines / antidepressants with H1 blockade (useful when depression or abuse risk is present): diphenhydramine (OTC), doxepin (TCA), mirtazapine, trazodone

Clinical approach / prescribing guidance

Acute anxiety / panic / breakthrough
- Use short-acting benzodiazepines for rapid relief (e.g., lorazepam, alprazolam, diazepam). Typically PRN and short-term because of abuse potential.
Chronic anxiety (GAD, social anxiety, panic disorder)
- Prefer SSRIs or SNRIs for long-term management (onset ~4–6 weeks). Use short-term PRN benzodiazepines for bridge therapy until antidepressant effect develops.
- Buspirone is an option for chronic anxiety when abuse risk is a concern (not effective for acute panic).
Insomnia selection
- Anxiety-related insomnia (racing mind): consider benzodiazepines (temazepam, flurazepam) but weigh abuse/dependence risk; avoid in patients with substance-use history.
- Mild–moderate non-anxiety insomnia needing minimal morning sedation: Z-drugs (zolpidem, zaleplon — zaleplon preferred when very short half-life is desired).
- Sleep induction only: melatonin receptor agonists (ramelteon).
- Depression-associated insomnia or high addiction risk: sedating antidepressants/antihistaminic antidepressants (doxepin, mirtazapine, trazodone).
- Avoid barbiturates for routine anxiolysis or hypnotic therapy.

Adverse effects, dependence, and interactions

CNS depression
- All sedative-hypnotics cause CNS depression; barbiturates can cause profound depression with no ceiling effect (risk of coma).
- Benzodiazepines have a ceiling for medullary depression but remain dangerous, especially with other depressants.
Dependence and tolerance (highest → lowest): barbiturates > benzodiazepines > Z-drugs.
Withdrawal and rebound
- Abrupt benzodiazepine cessation: rebound anxiety, insomnia, autonomic hyperactivity, tremor, seizures — requires gradual taper (taper strategies may use long-acting agents like diazepam).
- Barbiturate withdrawal can be life-threatening (seizures, severe rebound).
Overdose
- Benzodiazepine overdose: CNS and respiratory depression; reversible with flumazenil in appropriate settings.
- Barbiturate overdose: more severe; requires supportive and intensive care.
Drug interactions
- Barbiturates: strong CYP450 inducers → reduce efficacy of many drugs.
- Additive CNS depression with alcohol and other sedatives (potentially fatal).
Other adverse reactions
- Melatonin agonists: may increase prolactin (possible gynecomastia, menstrual irregularities).
- Z-drugs: some abuse/dependence potential (less than benzodiazepines).
- Orexin antagonists: limited long-term data; possible suicidal ideation and CYP450 metabolism considerations.

Key mechanistic takeaways (one-line summaries)

Anxiolysis: increase serotonin and/or GABA (target GABA-A alpha-2).
Hypnosis/insomnia: increase melatonin, increase GABA at alpha-1, and/or reduce orexin/histamine activity to permit VLPO-mediated sleep.
Benzodiazepines: increase frequency of GABA-A Cl– channel openings.
Barbiturates: increase duration of GABA-A Cl– channel openings.
Z-drugs: act at alpha-1 → predominantly hypnotic effects.
Avoid barbiturates for routine anxiety/insomnia because of toxicity, dependence, and CYP interactions.

Clinical pearls / testing points

SSRIs/SNRIs take ~4–6 weeks for anxiolytic effect — use short-term benzodiazepine cover if needed.
Buspirone is not effective for acute panic; useful for chronic anxiety with low abuse risk.
Zaleplon is short-acting — good for sleep induction with minimal next-day sedation.
Flumazenil reverses benzodiazepine effects (not opioids); naloxone reverses opioid overdose.
In alcohol-withdrawal seizures, benzodiazepines (lorazepam/diazepam) are commonly used; barbiturates may also be used in specific settings.

Sources / speakers

Video narrator: Ninja Nerds instructor (single, unnamed speaker; referred to the audience as “my friends” / “Ninja nerds”). No other distinct external speakers were featured.